Puma Biotechnology (PBYI) Cash & Current Investments (2011 - 2026)

Puma Biotechnology has reported Cash & Current Investments for 16 years, with the latest figure at $101.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 8.99% year-over-year to $101.5 million; the trailing twelve-month figure through Mar 2026 stood at $101.5 million (up 8.99% YoY), and the FY2025 full-year result was $97.5 million, up 40.9% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $101.5 million, up from $97.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $107.2 million in Q1 2024, with the low at $52.8 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $83.3 million across 5 years, with a median of $85.0 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 46.55% — and 2024, when it surged 50.47%.
• Puma Biotechnology's Cash & Current Investments stood at $81.1 million in 2022, then rose by 18.34% to $95.9 million in 2023, then decreased by 27.85% to $69.2 million in 2024, then jumped by 40.9% to $97.5 million in 2025, then gained by 4.12% to $101.5 million in 2026.
• The last three Cash & Current Investments figures came in at $101.5 million (Q1 2026), $97.5 million (Q4 2025), and $55.6 million (Q3 2025), per Business Quant data.